Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q1 EPS of $1.83, $0.35 better than the analyst estimate of $1.48. Revenue for the quarter came in at $116.36 million versus the consensus estimate of $111.47 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.